Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Essure Panel Stresses Need For Patient Follow-Up, But Stressed-Out Patients Say, ‘Recall It’

This article was originally published in The Gray Sheet

Executive Summary

An FDA advisory panel recommended a collection of activities to mitigate risk in the use of Bayer Healthcare’s Essure permanent contraceptive device, but dozens of patients describing hypersensitivity, extreme pain, insert migration, irregular bleeding, ectopic pregnancy and perforation events urged FDA to recall the device.


Related Content

FDA Says Bayer's Response To Essure Investigation Satisfactory; Approves Product Label
FDA 'Black Box' Labeling For Essure Highlights Adverse Events With Bayer Sterility Device
Six-Year Study Will Compare Bayer’s Essure With Tubal Ligation
FDA Essure Actions Draw Lawmaker Ire, Demand For Product Withdrawal
Next Steps For Bayer’s Essure Device Coming In February, FDA Says
FDA Investigating Attorney, Physician Beefs With Bayer’s Essure PMA
Expect Bayer To Get Heat At FDA Advisory Panel Over Essure Adverse Events, Doc Training


Related Companies